Table 2 Appendix 1.
TREATMENTS | Source (year) | Treatment Uptake in 2000 (average) | Source (year) | Relative Risk Reduction |
|---|---|---|---|---|
Acute myocardial infarction | ||||
Community cardiopulmonary resuscitation | UKHAS-Norris, 1998[1] | 46% | BRESUS-Tunstall-Pedoe[2] | 10% |
Hospital cardiopulmonary resuscitation | UKHAS-Norris, 1998[1] | 99% | BRESUS-Tunstall-Pedoe[2] | 30% or 15% average |
Thrombolysis alone or in Combination | UKHAS-Norris, 1998[1] | 35% | Collins(1996)[3] | 12% |
Aspirin | UKHAS-Norris, 1998[1] | 79% | Antithrombotic Trialists' Collaboration (2002)[4] | 15% |
Primary angioplasty | David Cunningham, Myocardial Infarction National Audit Project (MINAP) (2002) – personal communication | 4% | Keeley (2002)[5] | 30% |
Beta blocker | UKHAS-Norris, 1998[1] | 19% | Freemantle (1999)[6] | 4% |
ACE inhibitor | UKHAS-Norris, 1998[1] | 19% | Latini (2000)[7] | 7% |
Secondary Prevention in CHD Patients | ||||
Aspirin | Ryan(2001)[8] | 61% | Antithrombotic Trialists' Collaboration (2002)[4] | 15% |
Beta blocker | EUROASPIRE II(2001) [9;9] | 37% | Freemantle (1999)[6] | 23% |
ACE inhibitor | EUROASPIRE II(2001) [9;9] | 21% | Flather (2000)[10] | 23% |
Statin | Ryan(2001)[8] | 50% | Pignone (2000)[11] | 29% |
Warfarin | EUROASPIRE II(2001) [9;9] | 4% | Lau (1992)[12] | 15% |
Rehabilitation | EUROASPIRE II(2001) [9;9] | 30% | Taylor (2002) | 27% |
Chronic Angina | ||||
CABG surgery | Society of Cardiothoracic Surgeons of Great Britain and Ireland[13] | 100% | Yusuf (1994)[14] | 39% |
Angioplasty | British Cardiac Intervention Society(2002)[15] | 100% | Keeley (2002)[5] | 16% |
Aspirin | Ryan(2001)[8] | 50% | Antithrombotic Trialists' Collaboration (2002)[4] | 15% |
Statins | Ryan(2001)[8] | 10% | Pignone (2000)[11] | 29% |
Unstable Angina | ||||
Aspirin alone | 30% | Antithrombotic Trialists' Collaboration (2002)[4] | 15% | |
Aspirin & Heparin | 60% | Antithrombotic Trialists' Collaboration (2002)[4] | 15% | |
Platelet glycoproteinIIB/IIIA inhibitors | 50% | Boersma(2002)[18] | 9% | |
Heart Failure in the Hospital | (2002) | 46% | ||
ACE inhibitor | Clealand (2002)[19] | 58% | Flather (2000)[10] | 26% |
Beta blocker | Clealand (2002)[19] | 28% | Shibata (2001)[20] | 37% |
Spironolactone | Clealand (2002)[19] | 10% | Pitt (1999)[21] | 30% |
Aspirin | Clealand (2002)[19] | 50% | Antithrombotic Trialists' Collaboration (2002)[4] | 15% |
Statins | Clealand (2002)[19] | 32% | Pignone (2000)[11] | 29% |
Heart Failure in the Community | ||||
ACE inhibitor | Ellis (2001)[22] | 68% | Flather (2000)[10] | 26% |
Beta blocker | Cleland (2002)[19] | 17% | Shibata (2001)[20] | 37% |
Spironolactone | Cleland (2002)[19] | 12% | Pitt (1999)[21] | 41% |
Aspirin | Ellis (2001) [22] | 38% | Antiplatelet Trialists' Collaboration (1994)[23] | 15% |
Statin | Cleland (2002)[19] | 43% | Pignone[11] | 29% |
Hypertension | Health Survey for England 1998(2001)[24] | 59% | Collins (1990)[25] | 11% |
Statins for primary Prevention | Packham (2000)[26] | 3% | Pignone[11] | 29% |